Schering-Plough's asenapine cleared by FDA

11/26/2007 | MarketWatch

The FDA has accepted Schering-Plough Corp.'s new drug application for asenapine, an oral treatment for schizophrenia and symptoms of bipolar disorder. Schering-Plough owns rights to asenapine through Organon BioSciences NV, which it acquired last week.

View Full Article in:

MarketWatch

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC